284 related articles for article (PubMed ID: 6172913)
1. [Radioactive substances (32P and 89Sr) in the treatment of pain in bone metastases].
Flamm J; Burkert S
Z Urol Nephrol; 1981 Nov; 74(11):801-6. PubMed ID: 6172913
[TBL] [Abstract][Full Text] [Related]
2. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases.
Nair N
J Nucl Med; 1999 Feb; 40(2):256-61. PubMed ID: 10025832
[TBL] [Abstract][Full Text] [Related]
3. [Nuclear medicine therapy of bone metastases].
Kimmig B; Hermann HJ; Kober B
Rontgenblatter; 1983 Jul; 36(7):216-9. PubMed ID: 6622951
[TBL] [Abstract][Full Text] [Related]
4. [The efficacy of therapy using 89Sr-strontium chloride in 200 patients with bone metastases of a prostatic cancer].
Haesner M; Buchali K; Pink V; Lips H
Nuklearmedizin; 1992 Mar; 31(2):48-52. PubMed ID: 1373485
[TBL] [Abstract][Full Text] [Related]
5. Bone pain palliation with 85Sr therapy.
Giammarile F; Mognetti T; Blondet C; Desuzinges C; Chauvot P
J Nucl Med; 1999 Apr; 40(4):585-90. PubMed ID: 10210217
[TBL] [Abstract][Full Text] [Related]
6. Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma.
Breen SL; Powe JE; Porter AT
J Nucl Med; 1992 Jul; 33(7):1316-23. PubMed ID: 1613572
[TBL] [Abstract][Full Text] [Related]
7. [Influence of 89Sr on the cell immune function in patients with multiple bone metastases].
Wu YG; Ma QL; Liu GF
Hunan Yi Ke Da Xue Xue Bao; 2002 Jun; 27(3):277-8. PubMed ID: 12575316
[TBL] [Abstract][Full Text] [Related]
8. Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma.
Papatheofanis FJ
J Nucl Med; 1997 Aug; 38(8):1175-9. PubMed ID: 9255144
[TBL] [Abstract][Full Text] [Related]
9. Decreased serum E-selectin concentration after 89Sr-chloride therapy for metastatic prostate cancer bone pain.
Papatheofanis FJ
J Nucl Med; 2000 Jun; 41(6):1021-4. PubMed ID: 10855628
[TBL] [Abstract][Full Text] [Related]
10. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.
Sciuto R; Festa A; Rea S; Pasqualoni R; Bergomi S; Petrilli G; Maini CL
J Nucl Med; 2002 Jan; 43(1):79-86. PubMed ID: 11801708
[TBL] [Abstract][Full Text] [Related]
11. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.
Storto G; Klain M; Paone G; Liuzzi R; Molino L; Marinelli A; Soricelli A; Pace L; Salvatore M
Bone; 2006 Jul; 39(1):35-41. PubMed ID: 16434248
[TBL] [Abstract][Full Text] [Related]
12. Carcinoma of the prostate: the treatment of bone metastases by radioactive phosphorus (32P).
Ariel IM; Hassouna H
Int Surg; 1985; 70(1):63-6. PubMed ID: 4019087
[TBL] [Abstract][Full Text] [Related]
13. [Effectiveness of repeated systematic radiotherapy for generalized prostate cancer].
Kiselev EN; Korytova LI; Karelin MI
Vopr Onkol; 2005; 51(6):689-91. PubMed ID: 17037036
[TBL] [Abstract][Full Text] [Related]
14. Question of the month--January 1995. What is the optimal dose of 89Sr for bone pain palliation?
Khader Z
Nucl Med Commun; 1995 Apr; 16(4):306. PubMed ID: 7542759
[No Abstract] [Full Text] [Related]
15. Strontium-89 for treatment of painful bone metastasis from prostate cancer.
Altman GB; Lee CA
Oncol Nurs Forum; 1996 Apr; 23(3):523-7. PubMed ID: 8801513
[TBL] [Abstract][Full Text] [Related]
16. Strontium-89 (Metastron) versus external beam radiotherapy in patients with painful bone metastases secondary to prostatic cancer: preliminary report of a multicenter trial. UK Metastron Investigators Group.
Bolger JJ; Dearnaley DP; Kirk D; Lewington VJ; Mason MD; Quilty PM; Reed NS; Russell JM; Yardley J
Semin Oncol; 1993 Jun; 20(3 Suppl 2):32-3. PubMed ID: 7684863
[No Abstract] [Full Text] [Related]
17. [Preliminary application of strontium-89 for the treatment of bone metastases from prostate cancer].
Zhao W; Deng H; Jie P; Qing C; Zhang X
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2010 Dec; 27(6):1251-4. PubMed ID: 21374974
[TBL] [Abstract][Full Text] [Related]
18. [32P] diphosphonate dose determination in patients with bone metastases from prostatic carcinoma.
Potsaid MS; Irwin RJ; Castronovo FP; Prout GR; Harvey WJ; Francis MD; Tofe AJ; Zamenhof RG
J Nucl Med; 1978 Jan; 19(1):98-104. PubMed ID: 413889
[TBL] [Abstract][Full Text] [Related]
19. 85Sr contaminant as a reliable tracer of 89Sr for monitoring urinary radioactivity in patients treated with 89Sr for bone metastases.
De Agostini A; Mascaro L; Pizzocaro C; Panarotto MB; Bestagno M
J Nucl Biol Med (1991); 1993 Mar; 37(1):38-44. PubMed ID: 7687149
[TBL] [Abstract][Full Text] [Related]
20. [Palliative pain relief treatment for multiple bone metastases by strontium-89].
Nishio M
Nihon Rinsho; 2011 Jun; 69 Suppl 5():581-5. PubMed ID: 22208048
[No Abstract] [Full Text] [Related]
[Next] [New Search]
